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Abstract
The cytochrome P450 (CYP) epoxygenase enzymes CYP2J and CYP2C catalyze the epoxidation of
arachidonic acid to epoxyeicosatrienoic acids (EETs), which are rapidly hydrolyzed to
dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH). It is well-established
that CYP epoxygenase-derived EETs possess potent vasodilatory effects; however, the cellular
effects of EETs and their regulation of various inflammatory processes have become increasingly
appreciated in recent years, suggesting that the role of this pathway in the cardiovascular system
extends beyond the maintenance of vascular tone. In particular, CYP epoxygenase-derived EETs
inhibit endothelial activation and leukocyte adhesion via attenuation of nuclear factor-kappaB
activation, inhibit hemostasis, protect against myocardial ischemia-reperfusion injury, and promote
endothelial cell survival via modulation of multiple cell signaling pathways. Thus, the CYP
epoxygenase pathway is an emerging target for pharmacological manipulation to enhance the
cardiovascular protective effects of EETs. This review will focus on the role of the CYP epoxygenase
pathway in the regulation of cardiovascular inflammation, and 1) describe the functional impact of
CYP epoxygenase-derived EET biosynthesis and sEH-mediated EET hydrolysis on key
inflammatory process in the cardiovascular system, 2) discuss the potential relevance of this pathway
to pathogenesis and treatment of cardiovascular disease, and 3) identify areas for future research.
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1. Introduction
It is well-established that oxidative metabolism of arachidonic acid by cyclooxygenases (COX)
and lipoxygenases (LOX) to biologically active eicosanoids plays a critical role in the
regulation of various cellular and physiologic processes [1,2]. However, it is less well-known
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that enzymes from the cytochrome P450 (CYP) system also stimulate the formation of various
biologically active mediators and constitute a “3rd pathway” of arachidonic acid metabolism
[3,4]. The role of the CYP subfamily of enzyme in the hepatic metabolism of xenobiotics is
well-recognized; however, certain CYPs also catalyze the oxidative metabolism of various
endogenous substrates in extrahepatic tissue [5].
One important example in the cardiovascular system is the olefin epoxidation of arachidonic
acid to four epoxyeicosatrienoic acid (EET) regioisomers (5,6-, 8,9-, 11,12-, 14,15-EET) by
the CYP2C and CYP2J epoxygenase enzymes [4,6]. Soluble epoxide hydrolase (sEH,
Ephx2) rapidly hydrolyzes the EETs to their corresponding dihydroxyeicosatrienoic acid
(DHET) metabolites [7], which, in general, are much less biologically active than EETs (Figure
1). EETs are also readily incorporated into cellular membranes via esterification to
phospholipids for subsequent release by phospholipases [8]. Importantly, the CYP
epoxygenases and sEH are expressed and metabolically active in various tissues and cell types,
including endothelial cells and cardiomyocytes [6,7,9–11].
It is well-established that EETs possess potent vasodilatory effects, which are mediated by
smooth muscle cell hyperpolarization via the activation of calcium-sensitive potassium
channels (BKCa++) and more pronounced in the presence of inhibition of prostacyclin and nitric
oxide (NO) biosynthesis [12,13]. Consequently, CYP-derived EETs are regarded as one of the
primary endothelium-derived hyperpolarizing factors (EDHFs) [14]. The role of this pathway
in blood pressure regulation has also been established, such that mice lacking sEH
(Ephx2−/−) have significantly higher circulating EET levels and lower blood pressure compared
with wild-type mice [15,16], administration of a sEH inhibitor (sEHI) significantly lowers
blood pressure in various rodent models of hypertension [17,18], and Ephx2 is a susceptibility
gene for hypertension-associated heart failure in rodents [19]. Importantly, sEHIs are currently
in clinical development for the treatment of hypertension, with first-time-in-human studies
initiated in November 2007.
However, the cellular effects of CYP-derived EETs and their regulation of various
inflammatory processes have become increasingly appreciated in recent years, suggesting that
the role of this pathway in the cardiovascular system extends beyond the maintenance of
vascular tone. The primary objectives of this review are to 1) describe the functional impact
of CYP epoxygenase-derived EET biosynthesis and sEH-mediated EET hydrolysis on key
inflammatory process in the cardiovascular system, 2) discuss the potential relevance of this
pathway to pathogenesis and treatment of cardiovascular disease, and 3) identify areas for
future research.
2. Experimental strategies to potentiate CYP epoxygenase pathway function
Preclinical investigations evaluating the biological function of CYP-derived EETs in vitro have
relied on exogenous administration of EETs, transfection/overexpression of CYP
epoxygenases, and inhibition of sEH to potentiate the CYP epoxygenase pathway and
characterize their anti-inflammatory properties. First, direct EET administration has enabled
functional characterization of specific EET regio- and stereo-isomers; however, these epoxides
are rapidly hydrolyzed by sEH to their less biologically active DHET metabolites, and
consequently are not amenable to dosing in vivo. Second, overexpression the CYP2J or CYP2C
epoxygenases by transfection increases cellular EET biosynthesis, and has enabled functional
characterization of the human epoxygenase enzymes CYP2J2, CYP2C8 and CYP2C9 in in
vitro and ex vivo models; however, experimental limitations with this approach also exist.
Third, although EETs mediate many of their biological effects in a manner consistent with
activation of a Gαs-coupled receptor, an “EET receptor” has not been cloned to date [20].
However, availability of the putative EET receptor antagonist 14,15-epoxyeicosa-5(Z)-enoic
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acid (14,15-EEZE) has proven instrumental in the functional characterization of the CYP
epoxygenase pathway in vitro and ex vivo [21]. Fourth, pharmacological administration of a
sEHI [17,22] and deletion of the sEH gene (Ephx2−/− mice) [23,24] significantly increase
cellular EET levels in vitro and tissue and systemic EET levels in vivo. This pharmacological
strategy has enabled investigators to characterize the anti-inflammatory properties of CYP-
derived EETs in whole animal models, and is currently under investigation in Phase II clinical
trials.
3. CYP epoxygenase pathway and the regulation of cardiovascular
inflammation
3.1. Inhibition of endothelial activation and leukocyte adhesion
Endothelial activation, leukocyte-endothelial adhesion, and subsequent leukocyte
transmigration across the endothelium is a primary event in the vascular inflammatory response
and integral to the pathogenesis of cardiovascular diseases in humans, including
atherosclerosis, heart failure and hypertension [25]. An early report observed that 14,15-EET
administration enhanced adherence of U937 mononuclear cells to cultured endothelial cells
[26]. Subsequent studies have demonstrated that CYP epoxygenase-derived EETs, in particular
11,12-EET, significantly attenuate endothelial activation and leukocyte-endothelial
interactions in various model systems (Table 1) [11,27–31].
3.1.1. Inhibition of NF-κB activation—Importantly, activation of nuclear factor-kappaB
(NF-κB) is a central mediator of this process, which induces transcriptional up-regulation of
endothelial cytokine, chemokine and cellular adhesion molecule (CAM) expression and drives
the subsequent adherence of leukocytes to the endothelium [32]. Node et al. were the first to
demonstrate that CYP-derived EETs possess potent anti-inflammatory properties in the
vasculature via inhibition of NF-κB activation [11]. In cultured human umbilical vein
endothelial cells (HUVECs), 11,12-EET (100 nM) significantly attenuated endothelial cell-
surface expression of VCAM-1, E-selectin and ICAM-1 after stimulation with TNF-α (10 ng/
mL). Importantly, these effects were independent of the EDHF properties, since BKCa++
channel inhibition with charybdotoxin or iberiotoxin did not alter the impact of 11,12-EET on
TNF-α-induced VCAM-1 expression. Among the four EET regioisomers, 11,12-EET was the
most potent inhibitor of VCAM-1 up-regulation, followed by 8,9-EET and 5,6-EET.
Interestingly, 14,15-EET administration yielded no anti-inflammatory effect. Second, both
transfection of the human CYP epoxygenase CYP2J2, which increased cellular EET
biosynthesis, and exogenous administration of 11,12-EET significantly attenuated VCAM-1
promoter activation by TNF-α in a heterologous system. Third, intra-arterial infusion of 11-12-
EET (100 ng/kg/min × 5.5-hours) attenuated VCAM-1 expression in isolated perfused murine
carotid arteries 5-hours after intraperitoneal TNF-α (10 mcg/kg) administration, and
significantly reduced TNF-α stimulated U937 mononuclear cell adhesion to isolated, perfused
murine carotid arteries. Lastly, 11,12-EET significantly attenuated TNF-α stimulated IκB
kinase (IKK) activity, inhibitor κB-α (IκB-α) degradation, and subsequent RelA translocation
into endothelial cell nuclei, collectively demonstrating that CYP-derived EETs inhibit
cytokine-induced endothelial activation and leukocyte adhesion via inhibition of NF-κB
activation [11].
Subsequently, Fleming et al. confirmed that direct administration of 11,12-EET attenuated
TNF-α induced NF-κB activation in HUVECs [27]. Falck et al. demonstrated that 11,12-EET,
and a series of its structural analogues, inhibited TNF-α induced VCAM-1 expression in human
saphenous vein endothelial cells (HSVEC) [28]. Moreover, all four EET regioisomers (5,6-,
8,9-, 11,12-, and 14,15-EET) attenuated IκB-α degradation after TNF-α stimulation in bovine
aortic endothelial cells (BAECs) [29], further demonstrating that EETs inhibit cytokine-
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mediated NF-κB activation in endothelial cells. A recent investigation in cultured mouse aortic
endothelial cells (MAECs) observed that both transfection of the human CYP epoxygenase
CYP2J2 and direct administration of 8,9-EET attenuated homocysteine (Hcy)-induced matrix
metalloproteinase (MMP)-9 expression and activity, IκB-α degradation, RelA nuclear
translocation, and NF-κB-DNA binding [30]. Direct 14,15-EET administration attenuated
IκB-α degradation after TNF-α stimulation in a primary culture of human bronchi [33]. In
cultured neonatal cardiomyocytes, administration of an sEHI inhibited angiotensin II (AngII)-
stimulated RelA nuclear translocation [34].
Recent in vivo investigations have also demonstrated that inhibition of sEH-mediated EET
hydrolysis significantly attenuate inflammatory responses in rodents. Induction of circulating
cytokine (TNF-α, IL-6) and chemokine (MCP-5) concentrations, hepatic inducible nitric oxide
synthase (iNOS) and COX-2 expression, and mortality by intraperitoneal LPS administration
(10 mg/kg) was significantly attenuated in Ephx2−/− mice [23] and wild-type mice treated with
a sEHI [22]. Similarly, sEHI administration protected rats from tobacco smoke-induced airway
inflammation, including leukocyte infiltration into bronchial alveolar lavage fluid [35].
Although NF-κB activation was not directly measured in these studies, attenuation of LPS-
mediated up-regulation of these inflammatory responses in vivo is consistent with inhibition
of NF-κB activation. Moreover, sEHI treatment significantly attenuated myocardial IκB-α
phosphorylation, IκB-α degradation, and nuclear RelA expression in mice 6-weeks after
cardiac hypertrophy induced by thoracic aortic constriction [34]. Similarly, NF-κB activation
in kidney and urinary excretion of monocyte chemoattractant protein (MCP)-1 was
significantly attenuated in Ephx2−/− mice with deoxycorticosterone acetate plus high salt
(DOCA-salt)-induced hypertension [16]. Collectively, these studies have demonstrated that
CYP-derived EETs significantly attenuate pathologically relevant inflammatory responses in
the cardiovascular system, including endothelial activation and leukocyte adhesion, which is
mediated at least in part through inhibition NF-κB activation. However, future studies which
further elucidate these effects in vivo, and the underlying mechanisms, are needed.
3.1.2. Activation of PPAR-α and PPAR-γ—The peroxisome proliferator-activated
receptor (PPAR) transcription factors are members of the nuclear receptor superfamily which
are activated by fatty acids and fatty acid derivatives, and are expressed in the vasculature and
myocardium [36]. In addition to regulating lipid utilization, adipocyte differentiation and
insulin sensitivity, PPAR-α and PPAR-γ elicit various anti-inflammatory effects upon
activation including inhibition of NF-κB activation, CAM expression and leukocyte-
endothelial adhesion [36–40]. Recent studies have demonstrated that all four EET and DHET
regioisomers bind to the isolated ligand-binging domains, transactivate PPAR-α and PPAR-
γ, induce PPAR/RXR heterodimer binding to a peroxisome proliferator response element
(PPRE), and activate downstream PPAR-responsive gene expression in vitro [29,41–44].
Interestingly, 14,15-DHET was the most potent transactivator of both PPAR-α and PPAR-γ
[43,44]. Moreover, further metabolism of EETs by CYP ω-hydroxylase (CYP4A) enzymes to
their corresponding ω-alcohol metabolites also bind to and activate PPAR-α [41],
demonstrating that downstream metabolic products may contribute to these effects.
Recent studies have demonstrated that PPAR-γ activation contributes to the anti-inflammatory
effects of CYP-derived EETs. Liu et al. observed that phospholipase A2 (PLA2) and CYP
epoxygenase inhibition attenuated laminar flow-activation of PPAR-γ [45], and laminar flow
augmented cellular EET levels and decreased sEH mRNA in cultured BAECs [29]. Moreover,
administration of the PPAR-γ antagonist GW96625 abolished the attenuation of TNF-α
induced IκB-α degradation in BAECs produced by EET administration, suggesting that
inhibition of NF-κB activation by EETs in endothelial cells may be mediated, at least in part,
by PPAR-γ activation. However, this remains to be confirmed in vivo. Similar studies
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evaluating the contribution of PPAR-α activation to the anti-inflammatory effects of EETs are
also necessary.
3.1.3. Increase HO-1 expression—Heme oxygenase (HO-1), the rate-limiting enzyme in
the catabolism of heme, has important anti-oxidant, anti-inflammatory and vasodilatory
properties in the vasculature [46–48]. The overlapping biological activities between EETs and
the HO system have led researchers to evaluate the potential contribution of HO-1 to the
properties of CYP-derived EETs in the cardiovascular system. Direct 11,12-EET
administration increased HO-mediated carbon monoxide production by rat mesenteric arteries
[49]. Moreover, HO inhibition abolished (8,9-, 11,12-EET) and partially inhibited (14,15-EET)
BKCa++ mediated dilation of rat mesenteric arteries by EETs [49], demonstrating the
contribution of HO activity to the vascular effects of EETs. Similarly, 8,9- and 11,12-EET
administration significantly increased HO-1, but not HO-2, expression and activity in cultured
endothelial cells and rat aortas [50]. Overexpression of HO-1 in rat kidney has been reported
to suppress CYP expression and inhibit CYP epoxygenase metabolic activity [51], suggesting
the potential presence of a feedback control mechanism [50]. However, the contribution of
increased HO-1 expression to the anti-inflammatory effects of CYP-derived EETs has not been
explored to date.
3.1.4. Increase eNOS expression—The impact of CYP-derived EETs on the regulation
of vascular tone are most pronounced in the presence of endothelial nitric oxide synthase
(eNOS) inhibition [12,13], suggesting that these EDHFs serve as an important reserve system
to NO. In fact, EET-mediated vasodilation is hypothesized to play a substantially larger role
in the presence of established endothelial dysfunction and reduced NO availability, since NO
inhibits CYP enzymatic activity [52] and attenuates the release of EDHF [53]. Moreover, CYP-
derived EETs increased eNOS expression and NO biosynthesis in endothelial cells in vitro
[54,55], suggesting the presence of a functional interaction between these parallel pathways.
This was first reported by Wang et al. in cultured BAECs incubated with EETs (50–200 nM)
or transfected with CYP epoxygenase enzymes, which led to increased eNOS mRNA and
protein expression and increased metabolic conversion of L-arginine to L-citrulline [54].
Although increased eNOS Thr495 phosphorylation, which inhibits eNOS activity, was also
observed the net effect was an increase in eNOS metabolic activity [54]. These effects were
mediated by activation of mitogen-activated protein kinase (MAPK) and protein kinase C
(PKC) signaling [54]. Similarly, 11,12-EET has been reported to increase NOS activity in
human platelets in vitro [56]. Although increased NO biosynthesis may contribute to the
vasodilatory effects of EETs in certain vascular beds [55], the mechanistic contribution of
increased eNOS expression and NO generation to the anti-inflammatory effects of EETs
remains unclear and requires further investigation.
3.1.5. Decrease COX-2 mediated inflammatory responses—Multiple studies have
demonstrated that CYP-derived EETs inhibit COX-2-mediated inflammatory responses via
direct inhibition of COX-2 metabolic activity and/or attenuation of NF-κB-mediated up-
regulation of COX-2 expression. Administration of 11,12-EET dose-dependently attenuated
LPS-stimulated prostaglandin E2 (PGE2) production through inhibition of COX-2 activity, and
pharmacological blockade of CYP epoxygenase activity has augmented LPS-induced synthesis
of PGE2 in cultured rat monocytes [57,58]. Similarly, 14,15-EET administration decreased
PGE2 production in cultured murine brain microvascular smooth muscle cells without altering
COX-1 or COX-2 expression [59]. Administration of a sEHI significantly attenuated LPS-
mediated induction of hepatic COX-2 expression and circulating PGE2 levels in mice [22,
60]. Moreover, sEHI administration attenuated LPS-induced spinal COX-2 expression [61]
and intracerebroventricular (ICV) injection of EETs attenuated LPS-induced fever [58] in rats
in vivo, collectively demonstrating that potentiation of the CYP epoxygenase pathway
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attenuates COX-2 mediated inflammatory responses. These anti-inflammatory effects appear
to occur via attenuation of NF-κB-mediated induction of COX-2 expression and competitive
inhibition of COX-2 metabolic activity since EETs also are also weak substrates for COX
enzymes [62,63].
In contrast, Michaelis et al. observed that CYP2C9 overexpression increased COX-2 promoter
activity, COX-2 expression, prostacyclin production and cAMP levels by approximately 2-
fold in HUVECs under basal conditions, which were abolished by the CYP2C9-specific
inhibitor sulfaphenazole [64]. Direct 11,12-EET administration also significantly increased
COX-2 expression [64]. Importantly, these experiments were performed in the absence of an
inflammatory stimulus. As described above, CYP-derived EETs have been shown to inhibit
COX-2 expression and/or activity in the presence of inflammation. Further investigation
remains necessary to elucidate the mechanism underlying these contradictory findings and
characterize the functional interaction between COX-2 and the CYP epoxygenase pathway in
the vasculature and myocardium in vivo.
3.2. Inhibition of hemostasis
Overexpression of CYP2J2 via transfection and direct 11,12-EET administration (100 nM) to
BAECs significantly increased tissue plasminogen activator (t-PA) expression and activity via
activation of the cAMP-dependent kinase PKA and independent of endothelial cell
hyperpolarization [65]. No effect on plasminogen activator inhibitor (PAI)-1 was observed. In
parallel, CYP2J2 overexpression and 11,12-EET increased intracellular cAMP levels, cAMP-
response element (CRE) transactivation and Gαs GTP binding activity, further demonstrating
that the anti-fibrinolytic effects of EETs were mediated by cAMP activation [65]. Moreover,
inhibition of EET formation significantly attenuated thrombin-mediated t-PA release in human
microvascular endothelial cells [66]. In suspended platelets in vitro, EETs (1–10 μM) also
inhibited COX activity and arachidonic acid-induced platelet aggregation [67]. More recently,
overexpression of the human epoxygenase CYP2C9 and direct EET administration
hyperpolarized platelets (consistent with their EDHF properties), attenuated ADP-induced P-
selectin expression, and inhibited platelet adhesion to endothelial cells in a membrane
potential-dependent manner [68].
3.3. Protection against ischemia-reperfusion injury
Hypoxia-reoxygenation (H/R) or ischemia-reperfusion (I/R) injury induces inflammation
through multiple mechanisms and results in vascular and myocardial dysfunction. A series of
recent in vitro and in vivo studies have demonstrated that potentiation of the CYP epoxygenase
pathway protects endothelial cells and cardiomyocytes from I/R-induced injury [69]. In
cultured BAECs, overexpression of the human CYP2J2 epoxygenase and direct 11,12-EET
administration significantly attenuated H/R-induced oxidative stress and endothelial cell injury
[70]. Direct administration of EETs protected cardiomyocytes from H/R induced apoptosis in
vitro through activation of PI3K/Akt signaling [71]. Similarly, in isolated murine pulmonary
arteries and murine, rat and human myocardial tissue, H/R-induced apoptosis and injury was
significantly attenuated by 11,12-EET administration, and in Ephx2−/− mice, via activation of
PI3K/Akt signaling and ATP-sensitive potassium (KATP) channels [72].
Using the Langendorff isolated perfused heart model, post-ischemic recovery of contractile
function was significantly improved and deleterious electrocardiographic changes (e.g., QT
prolongation, ST elevation) and mitochondrial dysfunction (e.g., increased mitochondrial
fragmentation, T-tubule swelling) were significantly attenuated in transgenic mice with
cardiomyocyte-specific expression of the human CYP2J2 epoxygenase and with direct EET
administration to wild-type mice [73–75]. A similar cardioprotective phenotype has also been
observed in Ephx2−/− mice [24,75]. Moreover, direct administration of EETs into the perfusate
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or treatment with a sEHI significantly reduced the infarct size and inhibited the myocardial
remodeling after I/R injury in rodents and dogs [76–78]. Ephx2−/− mice exhibited an attenuated
suppression of left-ventricular ejection fraction and induction of cardiac arrhythmias in AngII
and thoracic aortic banding models of heart failure [19]. Recently, administration of an sEHI
improved contractile function, decreased infarct size, decreased atrial and ventricular
arrhythmias, and decreased induction of circulating cytokine and chemokine levels in mice 3-
weeks after a surgically-induced myocardial infarction by coronary artery occlusion [79].
Importantly, administration of the CYP epoxygenase enzyme inhibitor (MS-PPOH) and EET
receptor antagonist (14,15-EEZE) has abolished these phenotypes [24,72–78] in multiple
studies, demonstrating the direct contribution of CYP-derived EETs to cardioprotection.
These cardioprotective effects are mediated via activation of sarcolemmal and mitochondrial
KATP channels and activation of p42/p44 MAPK, PI3K and PKA signaling [24,72–75,77,
78], which are well-characterized cardioprotective mechanisms [69]. More recently, up-
regulation of b-type natriuretic peptide (BNP) expression and activation of natriuretic peptide
receptor type-A (NPR-A) has been shown to mediate the cardioprotective effects of EETs after
I/R injury, independent of PI3K [80]. Inhibition of sEH-mediated EET hydrolysis has also
significantly reduced cerebral infarct volume in rodents after middle cerebral artery occlusion
[81,82], an established preclinical model of ischemic stroke. Collectively, these studies
demonstrate that CYP-derived EETs offer substantial protection in preclinical models of I/R
injury, in addition to their known vasodilatory effects, further substantiating their anti-
inflammatory and protective properties in the cardiovascular system.
4. Vascular protective effects of the CYP epoxygenase pathway
4.1. Promotion of endothelial cell growth, survival, migration and angiogenesis
Recent studies have demonstrated that CYP-derived EETs promote endothelial cell survival
through potent pro-mitogenic, pro-migratory, pro-angiogenic [64,83–95] and anti-apoptotic
[71,72,96–98] effects, which has been the subject of recent reviews [20,99]. In addition to their
direct pro-angiogenic effects, CYP derived EETs also contribute to hypoxia-[88] and vascular
endothelial growth factor (VEGF)-mediated [93] stimulation of angiogenesis, further
demonstrating their important role in this process. These pro-survival effects are mediated
through activation of numerous cell signaling cascades in endothelial cells, including PI3K/
Akt, ERK and p38 MAPK (Table 2). Most notably, CYP-derived EETs are potent activators
of PI3K/Akt signaling, which is mediated via activation of the epidermal growth factor receptor
(EGFR) [87,90]. This leads to the downstream phosphorylation and inhibition of the forkhead
transcription factors FOXO1 and FOXO3b, downregulation of the cyclin-dependent kinase
inhibitor p27Kip1, and a subsequent increase in cyclin D1 expression [85]. CYP-derived EETs
also increase endothelial cyclin D1 expression via increased MAPK phosphatase-1 activation
and a subsequent decrease in JNK activity [84]. In parallel, induction of VEGF expression via
signal transducer and activator of transcription (STAT)-3 activation [95] and induction of
COX-2 expression via cAMP/PKA activation [64] have also been implicated in EET-induced
angiogenesis. Although these signaling pathways are also important regulators of inflammatory
responses, their contribution to the regulation of cardiovascular inflammation by CYP-derived
EETs remain unclear and require further investigation, particularly in cardiovascular disease-
specific in vivo models. Importantly, CYP-derived EETs have also been reported to promote
tumor metastasis [94], consistent with their pro-survival and pro-angiogenic effects, while
inhibition of CYP-derived EET formation has increased tumor cell apoptosis and decreased
tumor growth and metastasis [98]. These deleterious consequences of increased CYP-derived
EET formation require careful consideration and further investigation.
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4.2 Attenuation of vascular remodeling
In contrast to endothelial cells, potentiation of the CYP epoxygenase pathway has yielded
conflicting effects on the proliferation of vascular smooth muscle cells (VSMC) in vitro. In
human aortic VSMCs, sEH inhibition and direct EET administration decreased platelet-derived
growth factor (PDGF)-mediated stimulation of VSMC proliferation and cyclin D1 expression,
independent of p42/p44 MAPK phosphorylation [100]. In addition, overexpression of the
human CYP2J2 epoxygenase and direct 11,12-EET administration attenuated serum- and
PDGF-induced migration of rat aortic VSMCs via increased EET-mediated intracellular cAMP
generation and PKA activation [101]. These effects were independent of membrane
hyperpolarization and COX activity. However, no significant effect on PDGT-induced VSMC
proliferation was observed [101]. In contrast, 14,15-EET increased PDGF-induced
proliferation in porcine aortic SMCs via inhibiting COX-mediated PGE2 synthesis [59].
Although these conflicting results suggest that inter-species differences in the anti-proliferative
phenotype in VSMCs may exist, the mechanisms underlying the effects of CYP-derived EETs
on VSMC proliferation remain poorly understood.
Interestingly, two recent investigations have reported that sEHI administration in the drinking
water over 4 weeks significantly attenuated abdominal aortic aneurysm formation and
atherosclerotic lesion area in apolipoprotein E deficient mice receiving subcutaneous AngII
administration [102,103]; however, sEHI treatment had no effect on ligation-induced
remodeling of the carotid artery [103]. Atherosclerotic lesion area inversely correlated with
plasma 11,12- and 14,15- EET:DHET ratios, which are biomarkers of sEH metabolic activity
[102]. In addition, sEHI treatment downregulated pro-inflammatory gene expression in the
aorta and circulating levels in serum, and reduced inflammatory cell infiltration into the
vascular wall [103]. These data suggest that sEH-mediated EET hydrolysis may be important
in the pathogenesis of atherosclerosis, beyond their vasodilatory effects, via the regulation of
vascular inflammation. Importantly, future studies evaluating the effects of increased CYP
epoxygenase-mediated EET biosynthesis and decreased sEH-mediated EET hydrolysis remain
necessary to more fully understand the contribution of the CYP epoxygenase pathway to the
pathogenesis of atherosclerosis, vascular inflammation and vascular remodeling in vivo, and
further characterize the potential utility of therapies which modulate this pathway.
5. EET-independent effects of the CYP epoxygenase pathway and
inflammation
5.1. CYP-mediated reactive oxygen species generation
Certain CYP enzymes are also a known source of pro-inflammatory reactive oxygen species
(ROS), which enhance NF-κB activation and CAM expression [27,104]. In addition to the
biosynthesis of anti-inflammatory EETs, the CYP2C epoxygenases are also a significant source
of ROS in vitro and in vivo [27,105,106]. For instance, despite increasing EET biosynthesis,
overexpression of the human epoxygenase CYP2C9 increased ROS formation, NF-κB
activation and VCAM-1 expression in endothelial cells in vitro [27]. Administration of the
CYP2C-specific inhibitor sulfaphenazole decreased CYP2C-mediated ROS formation and
abolished these pro-inflammatory effects [27]. Similarly, sulfaphenazole significantly
attenuated myocardial injury and infarct size after I/R in rats [105], and enhanced endothelium-
dependent vasodilator responses in patients with coronary artery disease (CAD) via
suppression of ROS formation [106]. In contrast to the CYP2C epoxygenases, overexpression
of human epoxygenase CYP2J2 decreased ROS formation in BAECs under conditions of
enhanced oxidative stress [70]; although this anti-oxidant phenotype remains to be validated
in other model systems. Therefore, the enzymatic source of EETs may also be a critical factor
with respect to their net effect on inflammation, due to the potential for simultaneous ROS
production. However, direct comparisons of CYP2J and CYP2C-mediated EET biosynthesis
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on inflammatory responses in vivo, and the underlying mechanisms, have not been explored
and require further evaluation.
5.2. CYP epoxygenase metabolism of other fatty acids
In addition to arachidonic acid, linoleic acid is also metabolized by CYP epoxygenases to
epoxyoctadecenoic acids (EpOMEs), which are subsequently hydrolyzed by sEH to
dihydroxyoctadecenoic acids (DHOMEs). Importantly, plasma EpOME:DHOME ratios have
been validated as sensitive in vivo biomarkers of sEH activity in Ephx2−/− mice [24], rodents
treated with an sEHI [22,35], and in humans carrying functionally relevant EPHX2
polymorphisms [107], such that higher EpOME:DHOME ratios are indicative of lower sEH
metabolic activity. Interestingly, DHOMEs have been reported to elicit pro-inflammatory
effects in pre-clinical models [108,109]; however, it remains unclear whether decreased
EpOME hydrolysis to DHOMEs, in addition to decreased EET hydrolysis, significantly
contributes to the anti-inflammatory effects yielded by sEH inhibition.
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the 20 and 22-carbon ω-3
polyunsaturated fatty acid (PUFA) analogs of arachidonic acid, are also metabolized by CYP
epoxygenase enzymes to epoxyeicosatetraenoic acids (EETeTr) and epoxydocasapentaenoic
acids (EDP) respectively [110,111]. Interestingly, 17,18-EETeTr has been reported to possess
potent vasodilatory effects through activation of BKCa++ channels [111,112], suggesting that
CYP epoxygenase metabolism may contribute to the biological effects attributed to ω-3
PUFAs; however, the role of 17,18-EETeTr in the regulation of inflammation has not been
studied to date. Future studies will be required to delineate the direct contribution of arachidonic
acid-independent fatty acid metabolism to the regulation of cardiovascular inflammation by
the CYP epoxygenase pathway.
6. Effect of inflammation on the CYP epoxygenase pathway
It is well-established that acute inflammation significantly alters hepatic CYP expression in
vitro and in vivo [113–115]. In particular, cytokines suppress hepatic CYP expression in a pre-
translational manner, and consequently decrease xenobiotic metabolism and clearance in
preclinical models and humans [113–115]. Preclinical studies have also demonstrated that
extrahepatic CYP2C and CYP2J epoxygenase expression are suppressed in response to acute
inflammatory stimuli. For instance, pulmonary CYP2C11 and CYP2J4 expression were
significantly suppressed in the cecal ligation and puncture (CLP) sepsis model in rats [116].
Similarly, pulmonary CYP2J4 protein expression [117] and CYP-dependent arachidonic acid
metabolism [118] were suppressed in a rat model of Pseudomonas pneumonia, and renal CYP-
mediated EET formation was suppressed by 81% in LPS-treated rats compared to saline-treated
controls [119].
AngII also substantially impairs CYP epoxygenase pathway function in renal and vascular
tissue. Subcutaneous AngII infusion for 2-weeks significantly increased renal cortical sEH
protein expression in rats compared to untreated controls, which was paralleled by lower EET
and higher DHET levels in urine [17]. Similarly, AngII treatment significantly induced sEH
protein expression in HUVECs and BAECs in vitro and the aortic intima of rats in vivo
[120]. These changes were prevented by treatment with losartan, suggesting that this effect
was mediated by AT1 receptor activation [120]. The combination of AngII infusion and a high-
salt diet significantly suppressed CYP2C and CYP2J and increased sEH protein expression in
renal microvessels [121,122]. Blockade of TNF-α with etanercept prevented these changes in
CYP2C and sEH expression, while also reducing blood pressure, urinary protein and MCP-1
excretion, and renal leukocyte infiltration [121]. Moreover, in double transgenic rats (dTGR)
which overexpress the human renin and angiotensinogen genes, renal CYP2C and CYP2J
protein expression and EET formation was significantly lower compared to Sprague-Dawley
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control rats [123]. Treatment with fenofibrate, a PPAR-α activator, restored renal CYP2C
protein expression and epoxygenase metabolic activity in dTGRs to the levels observed
Sprague-Dawley rats, while also lowering blood pressure, renal inflammation and renal injury
[124]. In obese Zucker rats, CYP2C and CYP2J expression was also significantly lower and
sEH expression was higher in mesenteric arteries compared to Sprague-Dawley rats [125].
Similarly, renal tubule CYP2C protein expression and EET formation was significantly
decreased in a rat model of high fat diet-induced hypertension; although, EET formation in
renal microvessels remained unchanged in this model [126]. Lastly, sEH expression was
induced in aorta, heart, and lung of mice chronically exposed to tobacco smoke [127].
These studies collectively demonstrate that various inflammatory stimuli, including activation
of cytokines and the renin-angiotensin system, suppress CYP2C/2J and increase sEH
expression, suggesting that alterations in CYP epoxygenase pathway expression and function
may be an important consequence of inflammatory response in vivo. However, the specific
underlying mechanisms remain unclear. Extensive studies in hepatocytes and liver tissue
suggest that modulation of CYP expression by inflammatory stimuli is primarily transcription-
dependent; although, identification of the specific transcription factors which mediate these
alterations in CYP expression have yielded conflicting results and other mechanisms involving
RNA stability and interactions with NO may also contribute [128–130]. Importantly, the
functional implications of inflammation-induced changes in CYP and sEH expression on EET
levels in the cardiovascular system in vivo requires further investigation, including studies in
humans with cardiovascular disease.
7. Genetic variation and cardiovascular disease in humans
Genetic polymorphisms in EPHX2 and the human epoxygenases CYP2J2 and CYP2C8 with
altered expression or function have been recently identified [131]. We and others have observed
significant associations between these polymorphisms and risk of developing cardiovascular
disease in which inflammation plays an integral pathological role, including CAD and ischemic
stroke [131]. For example, a CYP2J2 proximal promoter polymorphism (−50G>T), which
results in loss of a critical Sp1 transcription factor binding site, reduced CYP2J2 transcription
and lowered plasma DHET levels, has been associated with significantly greater risk of CAD
[132,133]. In CYP2C8, the Arg139Lys/Lys399Arg (CYP2C8*3) variant results in lower
CYP2C8 catalytic activity in vitro [134], and has been associated with higher risk of prevalent
myocardial infarction [135] and incident CAD in cigarette smokers [136]. The EPHX2
Lys55Arg variant, which results in higher sEH-mediated EET hydrolysis in vitro [137], has
been associated with higher apparent sEH activity in vivo and increased risk of incident CAD
[107]. Associations between genetic variation in EPHX2 and coronary artery calcification, an
established measure of subclinical atherosclerosis [138], and incident ischemic stroke events
[139] have also been reported.
Collectively, these epidemiological analyses have demonstrated that genetic variation in the
CYP epoxygenase pathway is associated with cardiovascular disease risk at the population
level, suggesting that this pathway may also play an important role in the regulation of
cardiovascular inflammation in humans. However, the functional contribution of these genetic
variants to cardiovascular inflammation remains poorly understood and requires further study.
Moreover, conflicting reports regarding the presence and strength of these relationships have
been identified across studies, suggesting that these relationships are complex and likely most
profound in certain subsets of the population [131]. Interestingly, we and others have reported
that the association between CYP2J2, CYP2C8 and EPHX2 genetic variants and CAD risk are
consistently most pronounced in cigarette smokers [107,133,136,140], suggesting that the
pathological impact of lower CYP-derived EETs may be greatest in those with underlying
vascular dysfunction. Such an interaction would be consistent with the preclinical studies
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described above, since modulation of the CYP epoxygenase pathway appears to elicit its most
substantial effects on cardiovascular function in the presence of a pathological stimulus (e.g.,
cytokine activation, I/R injury, etc.). Future studies evaluating the impact of genetic variation
in the CYP epoxygenase pathway on prognosis in patients with established cardiovascular
disease will offer important insight into this question, and potentially identify subsets of the
population most likely to respond to therapies which modulate this pathway.
8. Summary and Future Directions
In recent years, the CYP epoxygenase pathway has been identified as an important regulator
of cardiovascular inflammation in addition to its more well-established role in the regulation
of vascular tone. The aforementioned preclinical studies have demonstrated that CYP
epoxygenase-derived EETs act in a paracrine and/or autocrine manner to inhibit endothelial
activation and leukocyte adhesion, inhibit hemostasis, attenuate myocardial I/R injury, and
promote endothelial cell survival via modulation of multiple cell signaling pathways (Figure
2). Most notably, CYP-derived EETs attenuate NF-κB activation and promote activation of
cAMP, PI3K/Akt, p42/p44 MAPK signaling in endothelial cells and cardiomyocytes. Although
it remains unclear whether these effects are mediated via binding to a putative EET cell-surface
and/or intracellular receptor, the collective preclinical evidence has demonstrated that
potentiation of the CYP epoxygenase pathway elicits protection against various pathological
stimuli in the cardiovascular system and has high potential for therapeutic application to various
cardiovascular diseases.
Despite these advances, important questions remain which require further exploration. First,
since most experiments to date have focused on the regulation of inflammatory responses in
vitro, confirmation of these anti-inflammatory phenotypes and the underlying mechanisms in
cardiovascular disease-relevant models in vivo remain necessary. Although the short half-life
of EETs limit their bioavailability in vivo, the recent development of sEHIs conducive for in
vivo dosing and transgenic/knockout rodent models have provided investigators the tools
necessary to complete such studies. Second, identification of the putative EET receptor will
enable the development of specific EET receptor agonists and antagonists, and substantially
accelerate future research in this field. Third, further evaluation of interactions between the
CYP epoxygenase pathway and parallel pathways known to regulate cardiovascular
inflammation in vivo, including eicosanoid metabolism (e.g., COX-derived prostaglandins,
LOX-derived leukotrienes) and non-eicosanoid metabolism (e.g., NO, renin-angiotensin
system) pathways, remain necessary to more fully elucidate the net functional contribution of
the CYP epoxygenase pathway to the pathogenesis and treatment of cardiovascular disease.
Fourth, the potentially deleterious consequences of increasing CYP-derived EETs, most
notably tumor development and metastasis, and the underlying mechanisms also require
rigorous investigation. Lastly, clinical studies will ultimately be required to truly understand
the functional role of the CYP epoxygenase pathway in the regulation of cardiovascular
inflammation in humans, and define the efficacy and safety of potentiating CYP-derived EETs
in patients with cardiovascular disease. Importantly, sEHIs are currently under investigation
for hypertension in Phase II clinical trials, and provide substantial promise for translation of
these preclinical findings into clinical trials.
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Figure 1. Overview of CYP Epoxygenase Pathway Metabolism
Upon cPLA2 activation, arachidonic acid is released and oxidatively metabolized by
cyclooxygenases (COX), lipoxygenases (LOX) and cytochromes P450 (CYP) into biologically
active eicosanoids. This review focuses on the CYP epoxygenase pathway. Isoforms from the
CYP2J and CYP2C subfamilies synthesize four epoxyeicosatrienoic acid (EET) regioisomers
(11,12-EET is shown), which are subsequently incorporated into membrane phospholipids or
rapidly hydrolyzed by soluble epoxide hydrolase (sEH) into their corresponding diol
dihydroxyeicosatrienoic acid (DHET) metabolites (11,12-DHET is shown). The DHETs
generally possess less potent biological activity than EETs.
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Figure 2. Overview of the Cardiovascular Protective Effects of CYP Epoxygenase-Derived EETs
A series of recent studies have demonstrated that CYP epoxygenase-derived EETs possess
potent cardiovascular protective effects including inhibition of endothelial activation and
leukocyte adhesion, inhibition of hemostasis, attenuation of myocardial and endothelial
ischemia-reperfusion (I/R) injury, and promotion of endothelial cell survival.
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Table 2
Summary of the key signaling pathways which mediate the pro-growth and pro-survival effects of CYP
epoxygenase-derived EETs on endothelial cells.
Signaling pathway Endothelial cell system Reference
↑ PI3K/Akt Human umbilical vein ECs [85,87,92]
Murine pulmonary microvascular ECs [89]
Bovine aortic ECs [90,97]
Human dermal microvascular ECs [91]
Human coronary artery ECs [96]
Human pulmonary microvascular ECs [96]
↑ ERK Porcine coronary artery ECs [83]
Human coronary artery ECs [83]
Human umbilical vein ECs [83,84]
Murine pulmonary microvascular ECs [89]
Bovine aortic ECs [90,97]
↑ p38 MAPK Porcine coronary artery ECs [83]
Human coronary artery ECs [83]
Human umbilical vein ECs [84]
Murine pulmonary microvascular ECs [89]
↑ MAPK phosphatase-1 / ↓ JNK Human umbilical vein ECs [84]
↑ cAMP/PKA Human umbilical vein ECs [64]
Cyclic adenosine monophosphate: cAMP; Epidermal growth factor receptor: EGFR; Extracellular signal-regulated kinase: ERK; c-Jun N-terminal
kinase: JNK; Mitogen-activated protein kinase: MAPK; Phosphatidylinositol 3-kinase: PI3K; Protein kinase A: PKA.
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